Aortic valve microcalcification and cardiovascular risk: an exploratory study using sodium fluoride in high cardiovascular risk patients

Autor: João L. M. P. de Lima, Lino Gonçalves, Antero J. Abrunhosa, Miguel Castelo-Branco, Manuel Oliveira-Santos, Nuno Chichorro, C Domingues, Maria João Ferreira, Rodolfo Silva, Andreia Gomes
Rok vydání: 2020
Předmět:
Male
Aortic valve
Fluorine Radioisotopes
medicine.medical_specialty
Percentile
Disease
030204 cardiovascular system & hematology
Risk Assessment
Lesion
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Predictive Value of Tests
Risk Factors
Positron Emission Tomography Computed Tomography
Internal medicine
Sodium fluoride
Humans
Medicine
Radiology
Nuclear Medicine and imaging
030212 general & internal medicine
Aged
business.industry
Calcinosis
Aortic Valve Stenosis
Middle Aged
Prognosis
medicine.disease
Stenosis
Clinical research
medicine.anatomical_structure
chemistry
Aortic Valve
Asymptomatic Diseases
Disease Progression
Cardiology
Sodium Fluoride
Female
Microcalcification
Radiopharmaceuticals
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Zdroj: The International Journal of Cardiovascular Imaging. 36:1593-1598
ISSN: 1573-0743
1569-5794
Popis: 18F-sodium fluoride (18F-NaF) has been used to access aortic stenosis in clinical research setting. It is known that its uptake is related with microcalcification. The purpose of this study was to assess the relationship between 18F-NaF uptake by the aortic valve and cardiovascular risk. Twenty-five patients with risk factors for cardiovascular disease, without known cardiovascular disease or aortic stenosis underwent PET-CT with 18F-NaF. Cardiovascular risk was assessed through the ASCVD (Atherosclerotic Cardiovascular Disease) risk calculator. Aortic valve 18F-NaF (AoVCUL) uptake was evaluated through the corrected uptake per lesion (CUL = max SUV - mean blood-pool SUV). Calcium score was obtained through cardiac CT. The patients present a mean age of 63.90 ± 8.60 years and 56% males. The mean ASCVD was of 28.76 ± 18.96 (M 25, IQR 38.50). The mean aortic valve calcium score (AoVCaSc) was of 53.24 ± 164.38 (M 6; IQR 29.75) and the AoVCUL was of 0.50 ± 0.10 (M 0.52, IQR 0.15). The patients were classified according to the ASCVD: patients with a risk greater or equal than the 50th percentile of the ASCVD risk and patients with a risk lower than the 50th percentile. The AoVCUL was evaluated in both groups: AoVCUL = 0.56 ± 0.10 vs 0.42 ± 0.15, p = 0.02; AoVCaSc was of 0 in 11 patients (44%) and those with an ASCVD greater or equal than the 50th percentile had a mean AoVCaSc of 8.00 ± 13.80, and those with an ASCVD risk lower than the 50th percentile had a mean AoVCaSc of 95.00 ± 223.45; p = 0.09. In this study microcalcification, evaluated through 18F-NaF on PET-CT, was related with cardiovascular risk. Although the score of calcium seems to be higher in higher cardiovascular risk patients, no significant difference was found between groups.
Databáze: OpenAIRE
Externí odkaz: